{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T11:14:22Z","timestamp":1780485262994,"version":"3.54.1"},"reference-count":16,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T00:00:00Z","timestamp":1717545600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Child Adolesc. Psychiatry"],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Autism spectrum disorder (ASD) is characterised by difficulty with social communication and restricted, repetitive patterns of behaviour. This study aimed to improve understanding of the ASD patient experience with the treatment (bumetanide) regarding the changes in core symptoms and to assess changes considered as meaningful. To achieve this, qualitative interviews were conducted with caregivers of patients in two phase 3 clinical trials (NCT03715153; NCT03715166) of a novel ASD treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Caregivers were invited to participate in one interview after completion of the pivotal phase 3 study; for those of them who continued treatment after study completion, a second interview was held 3 months after trial completion. The interviews were conducted by qualitative researchers and followed a semi-structured interview guide. The interviews focused on patients\u2019 ASD symptoms and their impact on their daily life before enrolment, and on any symptom changes patients experienced during the trial.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Out of the 13 eligible patients\u2019 caregivers, 11 were interviewed up to two times at clinical sites in the UK, Spain, and Italy. The caregivers reported impairments in a wide range of skills: deficits in communication and social interaction; restricted, repetitive patterns of behaviour, interests, or activities; and cognitive, emotional, and motor impairments. Compared to before the trial initiation, caregivers also reported improvements in the following domains: communication, interaction with others, cognition, aggression, emotions, repetitive movements, eating, and sleeping.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The exit interviews provided a rich source of qualitative data, allowing a deeper understanding of caregivers\u2019 and patients\u2019 experience of the disease and allowing us to understand what constitutes a meaningful change. These data also helped identify important experiences that may inform the patient-reported outcome measurement strategy for future trials in ASD.<\/jats:p><\/jats:sec>","DOI":"10.3389\/frcha.2024.1236340","type":"journal-article","created":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T19:33:27Z","timestamp":1718134407000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Exit interviews from two randomised placebo-controlled phase 3 studies with caregivers of young children with autism spectrum disorder"],"prefix":"10.3389","volume":"3","author":[{"given":"Natalia","family":"Hawken","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Falissard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl","family":"Choquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clement","family":"Francois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Tardu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramona","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,6,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.pharmthera.2018.05.007","article-title":"Autism spectrum disorder: classification, diagnosis and therapy","volume":"190","author":"Sharma","year":"2018","journal-title":"Pharmacol Ther"},{"key":"B2","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1207\/s15374424jccp3403_8","article-title":"Evidence-based assessment of autism spectrum disorders in children and adolescents","volume":"53","author":"Ozonoff","year":"2005","journal-title":"J Clin Child Adolesc Psychol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.ss7011a1","article-title":"Prevalence and characteristics of autism spectrum disorder among children aged 8 years\u2014autism and developmental disabilities monitoring network, 11 sites, United States, 2018","volume":"70","author":"Maenner","year":"2021","journal-title":"Morbidity Mortality Wkly Rep"},{"key":"B4","year":""},{"key":"B5","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1002\/aur.3005","article-title":"Bumetanide oral solution for the treatment of children and adolescents with autism spectrum disorder: results from two randomized phase III studies","volume":"16","author":"Fuentes","year":"2023","journal-title":"Autism Res"},{"key":"B6","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.jval.2016.11.005","article-title":"Clinician-reported outcome assessments of treatment benefit: report of the ISPOR clinical outcome assessment emerging good practices task force","volume":"20","author":"Powers","year":"2017","journal-title":"Value Health"},{"key":"B7","author":"Boyatzis","year":""},{"key":"B8","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/BF02408436","article-title":"Toward objective classification of childhood autism: Childhood Autism Rating Scale (CARS)","volume":"10","author":"Schopler","year":"1980","journal-title":"J Autism Dev Disord"},{"key":"B9","volume-title":"The Childhood Autism Rating Scale (CARS)","author":"Schopler","year":"1988"},{"key":"B10","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1023\/A:1025014929212","article-title":"Validation of a brief quantitative measure of autistic traits: comparison of the social responsiveness scale with the autism diagnostic interview-revised","volume":"33","author":"Constantino","year":"2003","journal-title":"J Autism Dev Disord"},{"key":"B11","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1007\/978-1-4419-1698-3_296","article-title":"Social responsiveness scale","volume-title":"Encyclopedia of Autism Spectrum Disorders","author":"Constantino","year":"2013"},{"key":"B12","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1111\/j.1469-7610.2012.02589.x","article-title":"Factors influencing scores on the social responsiveness scale","volume":"54","author":"Hus","year":"2013","journal-title":"J Child Psychol Psychiatry"},{"key":"B13","first-page":"28","article-title":"The clinical global impressions scale: applying a research tool in clinical practice","volume":"4","author":"Busner","year":"2007","journal-title":"Psychiatry (Edgmont)"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1111\/apa.15723","article-title":"Bumetanide for autism: open-label trial in six children","volume":"110","author":"Fernell","year":"2021","journal-title":"Acta Paediatr"},{"key":"B15","doi-asserted-by":"publisher","first-page":"313","DOI":"10.2147\/PROM.S385682","article-title":"Qualitative exploration in exit interviews of changes observed in clinical trials for individuals with autism spectrum disorder without intellectual disability","volume":"14","author":"Chladek","year":"2023","journal-title":"Patient Relat Outcome Meas"},{"key":"B16","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1007\/s00520-013-1824-5","article-title":"Association between hope and burden reported by family caregivers of patients with advanced cancer","volume":"21","author":"Utne","year":"2013","journal-title":"Support Care Cancer"}],"container-title":["Frontiers in Child and Adolescent Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/frcha.2024.1236340\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T19:33:31Z","timestamp":1718134411000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/frcha.2024.1236340\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,5]]},"references-count":16,"alternative-id":["10.3389\/frcha.2024.1236340"],"URL":"https:\/\/doi.org\/10.3389\/frcha.2024.1236340","relation":{},"ISSN":["2813-4540"],"issn-type":[{"value":"2813-4540","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,5]]},"article-number":"1236340"}}